Cellgram CKD
Alternative Names: Allogeneic bone marrow-derived mesenchymal stem cell therapy; Cellgram-CKD; Cellgram_CKDLatest Information Update: 28 Oct 2024
At a glance
- Originator Pharmicell
 - Developer Asan Medical Center; Pharmicell
 - Class Mesenchymal stem cell therapies
 - Mechanism of Action Angiogenesis modulating agents; Apoptosis inhibitors; Cell replacements; Immunogenetic modulators; Inflammation mediator modulators
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity No
 
Highest Development Phases
- No development reported Renal failure
 
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for phase-I development in Renal-failure in South Korea (IV, Injection)
 - 01 Nov 2021 Pharmicell plans a long-term follow-up study for Renal failure in South Korea (IV) (NCT05096182)
 - 16 Sep 2021 Phase I clinical trials in Renal failure in South Korea (IV) (NCT05042206) (Pharmicell pipeline, September 2021)